Abstract
Targeted therapies have provided the first agents that can overcome resistance to chemotherapy in metastatic colorectal cancer and have allowed for unprecedented survival rates in lung cancer. To date, the use of the VEGF inhibitor bevacizumab and the EGFR inhibitors cetuximab, panitumumab, gefitinib and erlotinib have been explored in various clinical settings. Bevacizumab has shown promising results in the treatment of breast cancer, colorectal carcinoma and renal cell carcinoma. Cetuximab, gefitinib and erlotinib are treatment options in non-small-cell lung cancer. Patients with metastatic colorectal cancer can derive great benefit from cetuximab or panitumumab therapy. However, patient selection is essential, since individual characteristics, such as KRAS mutation status, can determine response to treatment. Experts presented the current situation at the Annual Meeting of the Austrian Society of Surgical Oncology in St. Wolfgang, Austria, in October 2009
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
